afferon corp Pages on BioPortfolio:

BioPortfolio - novopharm usa inc
BioPortfolio - lineberry research BioPortfolio - novopharm usa inc t | gallbladder surgeons at La jolla Scripps | afferon corp | novopharm usa | sigma
. ...
http://www.bioportfolio.com/search/novopharm_usa_inc.html...

BioPortfolio - Urology
Afferon Corporation. Afferon is a privately held pharmaceutical company building a specialty pharmaceutical business focused on urology. ...
http://www.bioportfolio.com/indepth/Urology.html...

Results from other life science and pharmaceutical sites:

Afferon Corporation Enters Exclusive European Development and ...
WAYNE, Penn., May 3 /PRNewswire/ -- Afferon Corporation today announced that it has signed an exclusive European License, Product Development and Supply ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

Lower Urinary Tract Disorders - Ray Fuller Symposium Physiology ...
resiniferatoxin (ICOS Corp/Afferon Corp/NIH; Figure 4). initially activate afferent nerve fibers, they lead to rapid and. long-lasting desensitization. ...
http://www.biomedcentral.com/content/pdf/cd-464062.pdf...

Patent news Peter Steele
New or unfamiliar applicant names include such companies as. Afferon Corp (WO- 09909970), Aquila Biopharmaceuticals Inc. (WO-09910088),. Choa. (WO-09909932)
...
http://www.biomedcentral.com/content/pdf/cd-471639.pdf...

Future Trends in the Treatment of Urinary Incontinence
RTX, sponsored by the Afferon Corp. (Wayne, PA), is not clinically available and has completed only preliminary phase II, FDA trials in the United States. ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=14...

JP Morgan Hambrecht & Quist - 21st Annual Healthcare Conference ...
This product was in-licensed from Afferon Corp and is one. to watch as it meets current unmet needs; phase II trials. began enrolment on 7th January 2003. ...
http://www.biomedcentral.com/content/pdf/cd-478333.pdf...

Bladder Dysfunction Associated With Multiple Sclerosis
The prospect, therefore, of using intravesical resiniferatoxin (RTX®, Afferon Corporation, Scottsdale, AZ), an ultra-potent capsaicinoid[56] that is thought
...
http://www.medscape.com/viewarticle/515091_3...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.